Literature DB >> 36178567

Primary Care Providers and Nonalcoholic Fatty Liver Disease: A Needs Assessment Survey.

Kendall B Islam1, Danielle Brandman2, Janet N Chu3, Max L Goldman4, Rena K Fox5.   

Abstract

BACKGROUND: Primary care providers (PCPs) face increasing numbers of patients at risk for NAFLD and are responsible for the detection of NAFLD and the decision on referral to specialists. We conducted a PCP needs assessment to ascertain the barriers and desired supports for NAFLD in primary care.
METHODS: We designed a cross-sectional study of PCPs at a large diverse health system and surveyed faculty, residents, and nurse practitioners. Questions assessed NAFLD knowledge, approach to diagnosis and fibrosis testing including use of FIB-4, and attitudes toward support tools.
RESULTS: The survey was sent to 115 PCPs with an 80% (n = 92) response rate. Respondents were 52% faculty and 48% residents. Over 40% were unsure of which diagnostic tests to order and which data constituted a diagnosis. PCPs were aware of the importance of fibrosis, yet few knew the components of FIB-4, few used FIB-4 in practice, and yet the most common reason for referral was to obtain fibrosis staging. The majority showed high levels of interest toward possible tools to improve NAFLD management, and only 5% perceived lack of time to be a barrier. DISCUSSION: Our survey revealed PCPs need and want strategic approaches to NAFLD. We found PCPs lack confidence in diagnosing NAFLD and are inconsistent in management strategies. PCPs had high awareness of the importance of fibrosis, but not of the FIB-4. It was encouraging that PCPs reported that time was not a major barrier and had positive attitudes toward potential practice support tools, indicating that practice guidelines designed for primary care should be created.
© 2022. The Author(s).

Entities:  

Keywords:  Fatty liver; Implementation science; NAFLD; Noninvasive fibrosis assessment; Primary care

Year:  2022        PMID: 36178567     DOI: 10.1007/s10620-022-07706-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  8 in total

1.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

Review 2.  Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities?

Authors:  Mohamed H Ahmed; Emmanuel O Abu; Christopher D Byrne
Journal:  Prim Care Diabetes       Date:  2010-03-17       Impact factor: 2.459

Review 3.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

4.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

Review 5.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Authors:  Parambir S Dulai; Siddharth Singh; Janki Patel; Meera Soni; Larry J Prokop; Zobair Younossi; Giada Sebastiani; Mattias Ekstedt; Hannes Hagstrom; Patrik Nasr; Per Stal; Vincent Wai-Sun Wong; Stergios Kechagias; Rolf Hultcrantz; Rohit Loomba
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

6.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

Review 7.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 8.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.

Authors:  Chris Estes; Homie Razavi; Rohit Loomba; Zobair Younossi; Arun J Sanyal
Journal:  Hepatology       Date:  2017-12-01       Impact factor: 17.425

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.